TapewireFind a company

person · Reporting owner

Howton David T

Disclosed activity across 3 companies

Tapewire entity
16816
SEC CIK
0001529297

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Sarepta Therapeutics, Inc.SRPT · Entity 4426EVP, General CounselJune 22, 2020June 23, 2020
Solid Biosciences Inc.SLDB · Entity 4915Chief Operating OfficerJanuary 29, 2026April 21, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875SVP & Chief Legal OfficerFebruary 02, 2012February 06, 2012

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sarepta Therapeutics, Inc.

Report date June 22, 2020 · Filed June 23, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect31,871 Ending reported balance After 2020-06-22 transaction · row 8
8 source rows · reconciled sequence

Row 1 · 2020-06-22 · Exercise / conversion · Acquired 1,280 · Balance 33,151

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Row 2 · 2020-06-22 · Exercise / conversion · Acquired 1,858 · Balance 35,009

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Row 3 · 2020-06-22 · Exercise / conversion · Acquired 56,984 · Balance 91,993

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Row 4 · 2020-06-22 · Exercise / conversion · Acquired 45,000 · Balance 136,993

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Row 5 · 2020-06-22 · Sale · Disposed 6,009 · Balance 130,984

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Row 6 · 2020-06-22 · Sale · Disposed 8,086 · Balance 122,898

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Row 7 · 2020-06-22 · Sale · Disposed 35,757 · Balance 87,141

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Row 8 · 2020-06-22 · Sale · Disposed 55,270 · Balance 31,871

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28Direct0 Reported balance After 2020-06-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-06-22 · Exercise / conversion · Disposed 1,280 · Balance 0

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28Direct0 Reported balance After 2020-06-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2020-06-22 · Exercise / conversion · Disposed 1,858 · Balance 0

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2022-11-05Direct0 Reported balance After 2020-06-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2020-06-22 · Exercise / conversion · Disposed 56,984 · Balance 0

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.03 · Expires 2024-02-28Direct7,708 Reported balance After 2020-06-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2020-06-22 · Exercise / conversion · Disposed 45,000 · Balance 7,708

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Solid Biosciences Inc.

Report date January 29, 2026 · Filed April 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect79,341 Reported balance After 2026-01-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-29 · Grant · Acquired 79,341 · Balance 79,341

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

VERTEX PHARMACEUTICALS INC / MA

Report date February 02, 2012 · Filed February 06, 2012

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect19,437 Reported balance After 2012-02-02 transaction · row 1
1 source row

Row 1 · 2012-02-02 · Grant · Acquired 10,166 · Balance 19,437

F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $37.86 · Expires 2022-02-01Direct68,750 Reported balance After 2012-02-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2012-02-02 · Grant · Acquired 68,750 · Balance 68,750

F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.

Common StockSEC Table I · non-derivativeIndirect401(k)266 Reported balance Holding disclosure · report date 2012-02-02 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 266

Filing footnotes · ownership attribution and instrument terms

F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.

F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 18, 2026 Filed Feb 19, 2026 02:31 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 7,469 $5.82 $43,494.23
Disclosure

SEC source: 0001193125-26-057863 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,077

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Read SEC document
February 13, 2026 Filed Feb 19, 2026 02:31 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 14,687 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-057863 · ownership.xml · derivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,376

Underlying: Common Stock · 14,687 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F4 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F4 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
February 13, 2026 Filed Feb 19, 2026 02:31 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 14,687 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-057863 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
February 04, 2026 Filed Feb 6, 2026 23:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 18,894 $6.44 $121,713.26
Disclosure

SEC source: 0001193125-26-041523 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,859

F1 · shares: This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Read SEC document
February 02, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 37,771 $6.44 $243,128.15
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · nonDerivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,753

F3 · shares: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 42,275 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 7

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,825

Underlying: Common Stock · 42,275 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

F8 · derivative.exercise_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 169,100 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

F8 · derivative.expiration_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 169,100 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 42,275 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,254

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 105,100 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 6

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,100

Underlying: Common Stock · 105,100 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

F7 · derivative.exercise_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

F7 · derivative.expiration_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantEmployee Stock Option (Right to Buy) · Derivative 210,200 $0.00 Strike: $6.60 $0.00
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 5

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,200

Underlying: Common Stock · 210,200 shares

Expires 2036-01-29

F6 · derivative.exercise_date: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionPerformance Stock Units · Derivative 79,341 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 4

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 79,341 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

F5 · derivative.exercise_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

F5 · derivative.expiration_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:12 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 79,341 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-034080 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

Read SEC document
January 29, 2026 Filed Apr 21, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 79,341 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-166736 · ownership.xml · derivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,341

Underlying: Common Stock · 79,341 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

F2 · derivative.expiration_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Read SEC document
December 03, 2025 Filed Dec 4, 2025 21:22 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 4,932 $5.11 $25,202.52
Disclosure

SEC source: 0001193125-25-308118 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,908

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

Read SEC document
December 02, 2025 Filed Dec 4, 2025 21:22 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 13,051 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-308118 · ownership.xml · derivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,052

Underlying: Common Stock · 13,051 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2025 Filed Dec 4, 2025 21:22 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 13,051 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-308118 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:16 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-109736 · ownership.xml · derivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

F1 · derivative.expiration_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:16 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantEmployee Stock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $6.17 $0.00
Disclosure

SEC source: 0000950170-25-109736 · ownership.xml · derivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-08-14

F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 5,561 $3.96 $22,021.56
Disclosure

SEC source: 0000950170-25-022196 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,789

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.

Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 14,687 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-022196 · ownership.xml · derivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,063

Underlying: Common Stock · 14,687 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 14,687 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-022196 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
January 31, 2025 Filed Feb 11, 2025 21:38 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 169,100 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017962 · ownership.xml · derivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,100

Underlying: Common Stock · 169,100 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:04 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 5,072 $5.60 $28,396.10
Disclosure

SEC source: 0000950170-24-133340 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,663

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Mr. Howton.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:04 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 13,051 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-133340 · ownership.xml · derivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,103

Underlying: Common Stock · 13,051 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:04 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 13,051 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-133340 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,735

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
February 13, 2024 Filed Feb 16, 2024 16:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 58,750 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016193 · ownership.xml · derivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,750

Underlying: Common Stock · 58,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
February 13, 2024 Filed Feb 16, 2024 16:28 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantEmployee Stock Option (Right to Buy) · Derivative 117,500 $0.00 Strike: $7.85 $0.00
Disclosure

SEC source: 0000950170-24-016193 · ownership.xml · derivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,500

Underlying: Common Stock · 117,500 shares

Expires 2034-02-13

F1 · derivative.exercise_date: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

Read SEC document
December 04, 2023 Filed Dec 5, 2023 19:32 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 5,367 $2.78 $14,920.26
Disclosure

SEC source: 0000950170-23-068067 · ownership.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,684

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

Read SEC document
December 02, 2023 Filed Dec 5, 2023 19:32 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 13,051 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-068067 · ownership.xml · derivative · entry 3

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,154

Underlying: Common Stock · 13,051 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2023 Filed Dec 5, 2023 19:32 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 13,051 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-23-068067 · ownership.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
December 02, 2022 Filed Dec 5, 2022 22:50 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 52,205 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-037686 · doc4.xml · derivative · entry 2

Howton David T · CIK 0001529297 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,205

Underlying: Common Stock · 52,205 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2022 Filed Dec 5, 2022 22:50 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantStock Option (Right to Buy) · Derivative 104,410 $0.00 Strike: $6.77 $0.00
Disclosure

SEC source: 0000899243-22-037686 · doc4.xml · derivative · entry 1

Howton David T · CIK 0001529297 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,410

Underlying: Common Stock · 104,410 shares

Expires 2032-12-02

F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock option (right to buy) · Derivative 45,000 $0.00 Strike: $29.03 $0.00
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 12

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,708

Underlying: Common Stock · 45,000 shares

Expires 2024-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock option (right to buy) · Derivative 56,984 $0.00 Strike: $23.85 $0.00
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 11

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,984 shares

Expires 2022-11-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock option (right to buy) · Derivative 1,858 $0.00 Strike: $13.71 $0.00
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 10

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,858 shares

Expires 2026-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock option (right to buy) · Derivative 1,280 $0.00 Strike: $13.71 $0.00
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 9

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,280 shares

Expires 2026-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 55,270 $171.50 $9,478,805.00
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 8

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,871

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F5 · price: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 35,757 $170.59 $6,099,786.63
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 7

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,141

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F4 · price: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 8,086 $169.56 $1,371,062.16
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 6

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,898

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F3 · price: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 6,009 $168.61 $1,013,177.49
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 5

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,984

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

F2 · price: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 45,000 $29.03 $1,306,350.00
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 4

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 56,984 $23.85 $1,359,068.40
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 3

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 1,858 $13.71 $25,473.18
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
June 22, 2020 Filed Jun 23, 2020 01:17 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 1,280 $13.71 $17,548.80
Disclosure

SEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,151

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
February 28, 2020 Filed Feb 29, 2020 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock option (right to buy) · Derivative 37,500 $0.00 Strike: $114.47 $0.00
Disclosure

SEC source: 0001209191-20-014224 · doc4.xml · derivative · entry 2

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2030-02-28

F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant.

Read SEC document
February 28, 2020 Filed Feb 29, 2020 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 6,700 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-014224 · doc4.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,871

F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date.

F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date.

Read SEC document
December 13, 2019 Filed Dec 18, 2019 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock option (right to buy) · Derivative 59,421 $0.00 Strike: $23.85 $0.00
Disclosure

SEC source: 0001209191-19-061049 · doc4.xml · derivative · entry 5

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,984

Underlying: Common Stock · 59,421 shares

Expires 2022-11-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
December 13, 2019 Filed Dec 18, 2019 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionStock option (right to buy) · Derivative 18,579 $0.00 Strike: $13.90 $0.00
Disclosure

SEC source: 0001209191-19-061049 · doc4.xml · derivative · entry 4

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,579 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
December 13, 2019 Filed Dec 18, 2019 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 SaleCommon Stock 78,000 $125.50 $9,789,000.00
Disclosure

SEC source: 0001209191-19-061049 · doc4.xml · nonDerivative · entry 3

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,171

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
December 13, 2019 Filed Dec 18, 2019 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 59,421 $23.85 $1,417,190.85
Disclosure

SEC source: 0001209191-19-061049 · doc4.xml · nonDerivative · entry 2

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,171

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document
December 13, 2019 Filed Dec 18, 2019 01:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 18,579 $13.90 $258,248.10
Disclosure

SEC source: 0001209191-19-061049 · doc4.xml · nonDerivative · entry 1

Howton David T · CIK 0001529297 · EVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.